Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial

MLA

Faivre-Finn, Corinne, et al. “Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT) : An Open-Label, Phase 3, Randomised, Superiority Trial.” The Lancet Oncology, Jan. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2097..7f69917762169a0bf2c23d4e6d6186ed&authtype=sso&custid=ns315887.

APA

Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., Le Pechoux, C., McMenemin, R., Mohammed, N., O’Brien, M., Pantarotto, J., Surmont, V., van Meerbeeck, J., Woll, Lorigan, P., … Woll, P. J. (2017). Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial. The Lancet Oncology.

Chicago

Faivre-Finn, Corinne, Michael Snee, Linda Ashcroft, Wiebke Appel, Fabrice Barlesi, Adityanarayan Bhatnagar, Andrea Bezjak, et al. 2017. “Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT) : An Open-Label, Phase 3, Randomised, Superiority Trial.” The Lancet Oncology, January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2097..7f69917762169a0bf2c23d4e6d6186ed&authtype=sso&custid=ns315887.